OliX’s cp-asiRNA technology is RNAi triggering structure, offers a simple and elegant solution for the intracellular delivery of asiRNA with minimized adverse effects. Currently, OliX is developing locally administrable RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases at a lower cost and shorter time. We have also secured GalNAc-asiRNA to target various liver diseases.
Beginning with a license and collaboration agreement on an ophthalmic program OLX301A (2019), they recently signed an expanded agreement with Théa Open Innovation on OLX301A and OLX301D (2020), being recognized again as a global RNAi therapeutics company.